Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5966 Target Snapshot

IgG receptor FcRn large subunit p51 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
208Compounds
13Assays
0Approved Drugs
423.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

IgG receptor FcRn large subunit p51 shows approved-linked disease relevance led by Myasthenia gravis. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P55899. Start with Myasthenia gravis, then reuse UniProt P55899 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Myasthenia gravis, then reuse UniProt P55899 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 5 linked drugs
Open source guide
Disease program
Myasthenia gravis

IgG receptor FcRn large subunit p51 shows approved-linked disease relevance led by Myasthenia gravis. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with Myasthenia gravis because it currently carries approved-linked support. Linked drugs include BATOCLIMAB, EFGARTIGIMOD ALFA, NIPOCALIMAB, ORILANOLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats IgG receptor FcRn large subunit p51 as ChEMBL target CHEMBL5966, mapped to UniProt P55899. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
IgG receptor FcRn large subunit p51
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5966
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P55899
IgG receptor FcRn large subunit p51
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether IgG receptor FcRn large subunit p51 is the right protein anchor across sources, using UniProt P55899 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Myasthenia gravis is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameIgG receptor FcRn large subunit p51
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP55899
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelIgG receptor FcRn large subunit p51
UniProt AccessionP55899
Component TypeProtein
Sequence Length365 aa

IgG receptor FcRn large subunit p51

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as IgG receptor FcRn large subunit p51, mapped to UniProt P55899. Sequence length is 365 aa.

Mapped IDP55899
Review nameIgG receptor FcRn large subunit p51
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

IgG receptor FcRn large subunit p51 shows approved-linked disease relevance led by Myasthenia gravis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Myasthenia gravis
5 linked drugs · 5 direct · 5 efficacy
Linked drugBATOCLIMAB
Linked drugEFGARTIGIMOD ALFA
Linked drugNIPOCALIMAB
Linked drugORILANOLIMAB
Approved-linked Approved
immune system disease
1 linked drug · 1 direct · 1 efficacy
Linked drugEFGARTIGIMOD ALFA
Late clinical Phase III
autoimmune thrombocytopenic purpura
3 linked drugs · 3 direct · 3 efficacy
Linked drugBATOCLIMAB
Linked drugEFGARTIGIMOD ALFA
Linked drugROZANOLIXIZUMAB
Late clinical Phase III
Thrombocytopenia
3 linked drugs · 3 direct · 3 efficacy
Linked drugEFGARTIGIMOD ALFA
Linked drugNIPOCALIMAB
Linked drugROZANOLIXIZUMAB
Late clinical Phase III
Graves ophthalmopathy
2 linked drugs · 2 direct · 2 efficacy
Linked drugBATOCLIMAB
Linked drugEFGARTIGIMOD ALFA
Late clinical Phase III
bullous pemphigoid
1 linked drug · 1 direct · 1 efficacy
Linked drugEFGARTIGIMOD ALFA
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Myasthenia gravis because it currently carries approved-linked support. Linked drugs include BATOCLIMAB, EFGARTIGIMOD ALFA, NIPOCALIMAB, ORILANOLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseMyasthenia gravis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC50208.0
KD215.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1090633 8.8 IC50 1.6 Preclinical
CHEMBL1090632 8.62 IC50 2.4 Preclinical
CHEMBL1090970 8.62 IC50 2.4 Preclinical
CHEMBL2304309 8.59 IC50 2.6 Preclinical
CHEMBL1090278 8.41 IC50 3.9 Preclinical
CHEMBL1090640 8.41 IC50 3.9 Preclinical
CHEMBL1090968 8.38 IC50 4.2 Preclinical
CHEMBL1090638 8.34 IC50 4.6 Preclinical
CHEMBL1090636 8.33 IC50 4.7 Preclinical
CHEMBL2304310 8.32 IC50 4.8 Preclinical
Distribution

pChEMBL Value Distribution

56
5.0
60
5.5
43
6.0
29
6.5
13
7.0
4
7.5
9
8.0
4
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

13
Total Assays
188
Tested Compounds
1
Assay Types
Binding — 13 assays, 188 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 13 188 5.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine